Despite recent advances, current diagnostic tests and treatment of prostate cancer have limitations. In the last few years, numerous biomolecules have been investigated with the aim of improving diagnosis, including kallikrein-like proteases, growth factors and neuroendocrine markers. Analysis of susceptibility genes has also been a focus of attention. Extensive research into new therapeutic approaches is also underway, including targeting angiogenesis, immune regulation and stromal-epithelial interactions. Gene therapy, gene chip technology and proteomics have emerged as promising innovations. The host of novel diagnostic markers and therapies require appropriate validation, both phenotypical and functional. A further consideration is the need to re-evaluate clinical trial design and end points to facilitate progression of promising targets through the clinical trial process. Overall, the outlook for the treatment of prostate cancer looks promising, with any advances likely to require both a multimodal and multidisciplinary approach.
Introduction
Management of prostate cancer has been the subject of research since the early part of the last century. In the 1940s, the treatment of advanced prostate cancer was greatly progressed by Charles Huggins and colleagues 1 at the University of Chicago, with the recognition of the critical role of testosterone in stimulating the growth of prostate cancer cells. These findings led to the development of the first 'hormone' therapy for this diseasesurgical castration. Charles Huggins' pioneering work and related discoveries were rewarded by a Nobel Prize in 1966, and this work laid the foundations for the development of other hormonal treatments, including medical castration using luteinising hormone-releasing hormone analogues (LHRHa) and antiandrogen therapies.
In the last few years, science has revolutionised our understanding of prostate cancer, providing the technology required to allow elucidation of the processes involved. Indeed, great advances have been made in the diagnosis and treatment of this disease, with many new approaches under investigation. Nevertheless, though this is an enviable position compared with many other types of cancer, much more work is still needed. For example, questions remain regarding currently used diagnostic markers, while gaps exist in the prostate cancer armamentarium.
This review will discuss current options for the diagnosis and treatment of prostate cancer. The limitations of the different approaches will be highlighted, and the latest research in each area examined. initially used to monitor patients' responses to therapy. The European Association of Urology (EAU) guidelines on prostate cancer state that for nonpalpable prostate cancer, further investigation (ie prostate biopsies) should be performed when the PSA level is greater than 10 ng/ ml, and probably when it is above 4 ng/ml. 2 Although PSA is a good marker for prostate cancer, it is limited by poor tumour specificity: one in three cases of prostate cancer are associated with a normal PSA value, 3 while genetic polymorphisms can increase basal levels of PSA in individuals without prostate cancer. 4 Another issue associated with the diagnostic value of PSA is the difficulty in distinguishing between prostate cancer and benign prostate disorders, particularly in the intermediate PSA range (ie 4-10 ng/ml). 2 Digital rectal examination (DRE) This involves physical examination of the prostate, via the rectum, to identify abnormal changes (eg enlargement). Depending on the experience of the examiner, an abnormality detected during DRE signifies the presence of prostate cancer in only 15-40% of cases. 2 Moreover, it should be noted that DRE often underestimates tumour extension. Use of DRE in combination with PSA can considerably increase the probability of detecting prostate cancer. In one study, positive predictive values of 48.7 and 47.0% were observed for an abnormal finding during DRE and a PSA of greater than 4 ng/ml, respectively; the value increased to 80.0% when a combination of both was used. 5 Transrectal ultrasound (TRUS) This allows visualisation of the prostate. This technique can be used to identify malignant lesions but is most frequently used to guide and improve the accuracy of prostate biopsy. Diagnosis with TRUS is problematic given that the appearance of prostate cancer is variable, while only a few cancers will be detected with this technique if DRE and PSA levels are normal. 2 Biopsy and tumour grading and staging systems The Gleason system is a histological grading scheme used to measure the degree of differentiation of a tumour. 6 Tumours are allocated a grade ranging from one (small, uniform glands with minimal nuclear change) to five (undifferentiated tumour cells). The Gleason score is the summation of the two most widely represented grades and is defined as the most and second most predominant pattern of cancer. Measurement of the Gleason score requires a tissue sample, which can be obtained by needle biopsy or following radical prostatectomy. The latter provides more accurate results as the whole gland is removed, thus reducing the risk of undergrading. The Gleason score is a powerful prognostic indicator and influences treatment choice, 7 but has associated difficulties relating to interobserver reproducibility. 8, 9 There are two methods for staging tumours: the older Whitmore-Jewett classification and the more commonly used tumour-node-metastasis (TNM) system, which are mainly of benefit as a guide for treatment choice and prognosis. The TNM system describes the size/extent of the primary tumour (T stage; T1-T4), lymph node involvement (N stage; N0-N1) and the spread, or metastasis (M stage; M0-M1). The distinction between T1-T2 and T3-T4 disease is the most important in terms of treatment decisions. 2 
Potential new diagnostic tools
It is clear that the current methods used to diagnose prostate cancer have their limitations, resulting not only in missed cases of prostate cancer, but also in the diagnosis of cancers whose natural history is not likely to be life-threatening. Extensive research is ongoing to refine the current tools, and to develop new, more reliable tests.
Biological markers A number of different biological markers are under investigation for their potential to aid the diagnosis of prostate cancer and provide guidance on prognosis (Table 1) .
Two members of the kallikrein family of serine proteases, hK1 and hK2, may be of diagnostic use in conjunction with PSA which belongs to the same family. Insulin-like growth factor-1 (IGF-1) and IGF bindingprotein-3 (IGFBP-3) play an important role in the regulation of prostate cancer cell growth. However, whether these molecules represent tumour markers or aetiological factors has been a subject of debate. Several lines of evidence support a role for interleukin-6 (IL-6 ) in the development and progression of hormone-refractory prostate cancer, including the identification of both IL-6 protein and IL-6 receptors in prostate cancer specimens and the presence of high systemic levels in patients with disseminated disease. 10 Transforming growth factor b1 (TGF-b1) is important in regulating the proliferation and apoptosis of prostate epithelial and stromal cells. In early tumorigenesis, it functions as a tumour suppressor, and then as a tumour promoter in later stages of disease progression. Elevated expression is associated with poor clinical outcome.
11,12
Susceptibility genes It is well recognised that genetic risk factors exist for prostate cancer. However, identification of prostate cancer susceptibility genes has proven difficult given that most patients are elderly, and investigation of family lineages is consequently proble- Table 2 .
The elaC homologue 2 (ELAC2) gene was identified by a genomewide scan of large, high-risk prostate cancer pedigrees from Utah. 13 Overexpression of ELAC2 in tumour cells causes a delay in G2-M progression.
14 The ELAC2 gene product physically interacts with the gamma-tubulin complex, suggesting that it might promote tumorigenesis through irregular cell division. 14 
2
0 ,5 0 -oligoadenylate(2-5A)-dependent RNase L (RNA-SEL) degrades both cellular and viral RNA, and can induce apoptosis upon viral infection, whereas macrophage scavenger receptor 1 (MSR1) is responsible for cellular uptake of several charged molecules (eg bacterial cell wall products). 7 The exact role of RNASEL and MSR1 in the pathogenesis of prostate cancer is unclear. However, given that both are involved in the host response to infection, mutations in these genes may prevent adequate clearance of infection, resulting in chronic inflammation and potentially the development of prostate cancer. 15 Breast cancer gene 1 (BRCA1) and breast cancer gene 2 (BRCA2) are associated with the development of both prostate and breast cancer. BRCA1 is associated with a two-fold increase in relative risk for prostate cancer in men younger than 65 y;
16 BRCA2 with a seven-fold increase. 17 Somatic changes The diagnostic potential of somatic changes that occur in prostate cancer cells should not be forgotten, with changes becoming more common as the disease progresses. These changes can be in the form of mutation, differences in promoter methylation, or modification to the protein product.
7. Numerous pathways are affected including cell proliferation, cell survival, androgen metabolism, transcription repression and fatty acid metabolism. An indication of the genes involved is given in Table 2 , and more extensive information can be found in the recent review by DeMarzo et al.
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Of particular note is differential display code 3 (DD3PC A3 ), which is highly overexpressed in prostate cancer tumours, but is not expressed in normal human tissue.
18 DD3PC A3 could potentially play an important role in the early identification of malignancy. Use of a new molecular urine assay test to detect prostate cancer based on the presence of urinary DD3PC A3 showed a positive predictive value of 75% and a negative predictive value of 84%. 19 The future for diagnostic tools
The diagnostic tools discussed so far have mainly relied on the use of established scientific approaches. However, the latest technology-gene chip (DNA microarrays) 20 and proteomics 21 -has opened up completely new diagnostic avenues. These powerful tools are likely to accelerate identification of new molecular diagnostic and therapeutic targets.
Gene chip analysis allows the pattern of gene expression in tumours to be profiled, with thousands of genes monitored simultaneously. This technique can be used to compare the level and types of genes expressed in tumours compared with normal tissue, and to follow changes in prostate cancer cells during disease progression. Analysis to identify genes differentially expressed in normal, benign and cancer prostate cell lines showed that a variety of genes were up-or down-regulated in metastatic prostate tumour cells, with the majority encoding cytoskeletal and regulatory proteins. 22 Moreover, this study identified genes not previously associated with prostate cancer. Two important new genes have been identified using gene chip analysis, these are a-methylacyl-CoA racemase (AMACR) and enhancer of zeste homologue 2 (Drosophila) (EZH2). AMACR is upregulated in prostate cancer and has been shown to increase confidence in the diagnosis of malignant disease.
23 EZH2 also represents a new prognostic marker as it is expressed at higher levels in metastatic prostate cancer than in primary tumours. 24 Proteomics involves the analysis of subtle changes in proteins in tissue, serum or urine. Protein expression profiles are obtained using techniques such as mass spectrometry, followed by computer analysis. Proteomics can be used to identify changes in tumours vs normal tissue samples, and to differentiate between prostate cancer and benign conditions. For example, in a recent study, the proteomic pattern correctly predicted prostate cancer and benign conditions in 95 and 78% of patients, respectively. 25 
Treatment Established treatments
The EAU guidelines on prostate cancer describe the various treatment options available and recommend in which patients they should be used. 2 Watchful waiting is indicated: for patients with presumed localised disease; in asymptomatic patients with locally advanced disease, well or moderately differentiated cancer and short life expectancy; and very rarely for patients with metastatic disease. Radical prostatectomy should be undertaken in patients with a high probability of cure, and radiotherapy is also potentially curative in clinically localised disease (T1-T2). Hormonal treatments (eg surgical castration, LHRHa and antiandrogens) are indicated in patients with locally advanced or metastatic disease, and can be used as monotherapy or combination therapy, either alone or in conjunction with surgery or radiotherapy. It should be stressed that prior to treatment, it is important to discuss with patients factors such as life expectancy, quality-of-life expectations, health status and tumour characteristics, all of which have the potential to influence the choice of therapy. Moreover, the optimal therapy remains elusive, and patients need to understand the risks and benefits of different management approaches before they make a choice.
Treatments for prostate cancer are constantly evolving and are accompanied by improvements in disease prognosis. Nevertheless, despite these advances and the extensive research into prostate cancer, several gaps exist in the treatment options available, particularly for late-stage disease. Therefore, a number of potential therapeutic targets are being studied, with the aim of overcoming some of the limitations associated with current therapies. As with diagnostic markers, numerous targets are under investigation. Indeed, several of the markers discussed in relation to diagnosis are also promising in terms of treatment.
Future treatments
Potential therapeutic targets can broadly be categorised as involving the cancer cell itself or the cancer cell-host interaction, with examples given in Table 3 . However, before some of these are discussed in more detail, it must be stressed that a thorough understanding of the molecular pathway in which any potential target plays a role is mandatory. Moreover, appropriate validation of targets is vital. This encompasses both phenotypic validation (ie the target is overexpressed in the majority of cancers) and functional validation (ie the pathway targeted is pivotal for cancer cell survival or aggressiveness).
Another consideration is the role of prostate stem cells. Several lines of evidence support the hypothesis that prostate cancer arises from malignant transformation of intermediate stem cells. 26 If cancer stem cells indeed prove to be pivotal in prostate cancer, factors essential for their maintenance or renewal would be potential targets.
Cancer cell targets
Historically, the androgen receptor axis in cancer cells has been a focus of attention, and research in this area is still active. Targeting of growth factors (eg receptor inhibitors) is another focus, reviewed extensively elsewhere, 27, 28 with the mechanism of action based on the switch from paracrine to autocrine regulation that can occur in prostate cancer cells. Gene therapy is being actively pursued, 29 and is an attractive propositionparticularly given the numerous potential targets and the ease of access to the prostate. Gene therapy is discussed in more detail in another article in this Proceedings.
Cancer cell-host relationships
Stromal-epithelial interactions These are vital to all aspects of prostate regulation, from the development of the prostate in utero through to prostate cancer, metastasis and hormone-independence. Such interactions are multifactorial, involving extracellular matrix connections, direct communication and paracrine regulation. Agents such as the specific androgen receptor modulators (sARMs) and an adenoviral-osteocalcin promoter vector could be used to target both cancer cells and the stromal-epithelial interaction, with targeting of both elements simultaneously representing a unique approach to localised and metastatic cancer therapy. 30 Cadherins They are a class of cell adhesion molecule that maintain epithelial tissue differentiation and structural integrity. A study by Umbas et al showed that patients with aberrant E-cadherin staining of prostate cancer tumours had a significantly lower survival rate than patients with normal staining (Po0.001) at a mean follow-up of 36 months; 31 this difference was also evident after longer-term follow-up (Figure 1) . 32 Moreover, abnormal E-cadherin staining correlated significantly with disease progression after radical prostatectomy (Po0.005). 31 A 'cadherin switch' has been observed in tumour cells, in which the function of Ecadherin is replaced or overruled by mesenchymal cadherins, such as N-cadherin. 33 The result of this switch is that cells have the ability to become motile and invasive. Cadherins show great promise as a therapeutic target, with the challenge being to reverse the switch in types.
Angiogenesis The ability of a tumour to grow larger than 2 mm in diameter is dependent on both tumour cell proliferation and induction of new host-derived blood vessels (ie angiogenesis). Agents that inhibit angiogen- 34 A neutralising anti-VEGF antibody was shown to completely suppress prostate cancer-induced angiogenesis and prevent tumour growth beyond the initial prevascular growth phase. 34 Integrin receptor avb3 also plays a critical role in angiogenesis. 35 Indeed, integrin receptor avb3 antagonist antibodies have been shown to promote tumour regression in animal models, inducing apoptosis of angiogenic blood vessels. 36 Endogenous angiogenesis inhibitors such as plasminogen, which is proteolytically cleaved into angiostatin by tumours, and endostatin may prove effective therapies, but are likely to be most beneficial in combination with other forms of treatment. 27 Immune system targets Another potential treatment modality focuses on supporting the immune system, either through vaccination or the use of antibodies.
Vaccination can stimulate an antitumour response by recruiting a number of different arms of the immune system (eg cytotoxic T-lymphocytes (CTLs) and T-helper responses). The feasibility of anti-PSA vaccination has been investigated using several methods, such as dendritic cells pulsed with PSA, human leucocyte antigen-restricted PSA peptides, PSA-expressing recombinant viruses and cytokines. 37 HuJ591 is a mouse monoclonal antibody against prostate-specific membrane antigen, in which murine immunoglobulin sequences have been replaced with human equivalents. A Phase I study showed that HuJ591 is well tolerated, does not induce a host immune response and effectively targets disseminated prostate cancer sites. 38 HuJ591 has therapeutic potential in that it may be of use in targeting cytotoxic agents, such as toxins (eg ricin A-chain) or high-energy-emitting aparticles (eg bismuth-213), to prostate cancer cells.
Conclusions
It is clear from the level of research and development being undertaken that there is a strong commitment to tackling prostate cancer. However, many challenges are faced in translating the latest developments into effective patient therapies, with a multimodal and multidisciplinary approach a prerequisite of success. Moreover, a shift is necessary from the concept of treating populations as a whole to treating unique patients, in which the chosen therapy is relevant to the individual cancer phenotype.
A major challenge is ensuring that new, validated agents are introduced into clinical practice as quickly as possible. Indeed, the high number of potential agents and the many possible combinations raise several issues regarding the design of clinical trials. The progression of such agents through the clinical trial process needs to be facilitated, with clinical trial design and end points reevaluated. A 'clinical states model' has been suggested that provides a framework for matching agents with the treatment population's needs and tumour biology at different time points during progression of the disease. 39 The phenomenal advances made in recent years have provided the opportunity to once again greatly progress the treatment of prostrate cancer, building on the legacy of Charles Huggins. To ensure that effective treatments are available and targeted appropriately to each prostate cancer patient, these opportunities must be capitalised on. Future diagnosis and treatment of prostate cancer RWG Watson and JA Schalken
